NTLA
Intellia Therapeutics, Inc. Healthcare - Biotechnology Investor Relations →
Intellia Therapeutics, Inc. (NTLA) closed at $12.84 as of 2026-03-20, trading 53.3% below its 200-week moving average of $27.47. This places NTLA in the extreme value zone. The stock moved further from the line this week, up from -53.8% last week. The 14-week RSI sits at 66, indicating neutral momentum.
Trading volume is running at 1.0x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.92 ratio) is neutral — neither side is clearly dominating.
Over the past 467 weeks of data, NTLA has crossed below its 200-week moving average 6 times. On average, these episodes lasted 48 weeks. Historically, investors who bought NTLA at the start of these episodes saw an average one-year return of +315.2%.
With a market cap of $1517 million, NTLA is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -53.5%. The stock trades at 2.2x book value.
Share count has increased 33.5% over three years, indicating dilution.
Over the past 9 years, a hypothetical investment of $100 in NTLA would have grown to $88, compared to $314 for the S&P 500. NTLA has returned -1.4% annualized vs 13.6% for the index, underperforming the broader market over this period.
In the past 12 months, corporate insiders have made 2 open-market purchases totaling $2,405,500. Notably, these purchases occurred while NTLA is trading below its 200-week moving average — insiders are buying when the market is most pessimistic.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: NTLA vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After NTLA Crosses Below the Line?
Across 6 historical episodes, buying NTLA when it crossed below its 200-week moving average produced an average return of +255.7% after 12 months (median +44.0%), compared to +17.8% for the S&P 500 over the same periods. 50% of those episodes were profitable after one year. After 24 months, the average return was +64.0% vs +30.5% for the index.
Each line shows $100 invested at the moment NTLA crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
NTLA has crossed below its 200-week MA 6 times with an average 1-year return of +315.2% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Apr 2017 | Aug 2017 | 19 | 27.6% | +57.7% | -7.8% |
| Oct 2018 | Jun 2020 | 84 | 44.2% | -44.1% | -35.3% |
| Jul 2020 | Aug 2020 | 1 | 1.8% | +696.5% | -27.9% |
| Aug 2020 | Sep 2020 | 1 | 1.0% | +875.6% | -29.1% |
| May 2022 | Jun 2022 | 3 | 11.0% | -9.6% | -71.7% |
| Oct 2022 | Ongoing | 179+ | 87.2% | Ongoing | -74.4% |
| Average | 48 | — | +315.2% | — |
Frequently Asked Questions
Is NTLA below its 200-week moving average?
Yes. As of 2026-03-20, Intellia Therapeutics, Inc. (NTLA) is trading 53.3% below its 200-week moving average of $27.47. The current price is $12.84.
What is NTLA's 200-week moving average price?
Intellia Therapeutics, Inc.'s 200-week moving average is $27.47 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when NTLA drops below its 200-week moving average?
NTLA has crossed below its 200-week moving average 6 times in our data. On average, buying at that moment produced a one-year return of +315.2%. These dips have historically been decent entry points. These episodes lasted 48 weeks on average.
Is NTLA a good value right now?
Here's what our data says about NTLA as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 66. Free cash flow is currently negative. Return on equity is -53.5%. Price-to-book is 2.2x. This is not a buy or sell recommendation — always do your own research.
How does NTLA compare to the S&P 500?
Over the past 9 years, $100 invested in NTLA would have grown to $88, compared to $314 for the S&P 500. That's -1.4% annualized vs 13.6% for the index. NTLA has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20